Sanofi_Aventis_Genzyme.sff.jpg - Washington Times
Skip to content

FILE - In this Feb. 11, 2009 file photo, Chris Viehbacher CEO of Sanofi-Aventis SA, gestures while announcing the 2008 full year result in Paris. French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash deal that values the U.S. biotechnology company at $20.1 billion Wednesday, Feb. 16, 2011, ending months of corporate haggling. (AP Photo/Michel Euler, file)
Photo by: Michel Euler
FILE - In this Feb. 11, 2009 file photo, Chris Viehbacher CEO of Sanofi-Aventis SA, gestures while announcing the 2008 full year result in Paris. French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash deal that values the U.S. biotechnology company at $20.1 billion Wednesday, Feb. 16, 2011, ending months of corporate haggling. (AP Photo/Michel Euler, file)

Featured Photo Galleries

CounselGalleryCOVER.jpg

Special Counsels Rack Up Bills

Robert Mueller’s special counsel investigation into Russian meddling in the 2016 election has cost $6.7 million during the first four and a half months of the probe. Click to see past independent counsel investigations guilty of racking up high bills.